期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

下一代测序技术在淋巴瘤中的应用 被引量：1

Application of next-generation sequencing in lymphoma
原文传递
导出
摘要 淋巴瘤是发生于淋巴结和（或）结外淋巴组织的恶性肿瘤,是具有相当异质性的一大类肿瘤,随着分子生物学的不断发展,人们对淋巴瘤的发病机制、分类和预后等方面的认识也在不断的深入。同其他恶性增殖性疾病类似,淋巴瘤存在基因不稳定性,染色体异常是淋巴瘤发生发展的直接原因之一。
作者 崔国惠 吴要功
机构地区 华中科技大学同济医学院附属协和医院血液病研究所
出处 《临床血液学杂志》 CAS 2014年第6期931-935,共5页 Journal of Clinical Hematology
关键词 下一代测序技术 淋巴瘤 next-generation sequencing lymphoma
分类号 R733.4 [医药卫生—肿瘤]
  • 相关文献

参考文献31

  • 1SLACK G W,GASCOYNE R D.Next-generation sequencing discoveries in lymphoma[J] .Adv Anat Pathol,2013,20:110-116.
  • 2ABDELWAHAB O,GAO J,ADLI M.Conditional deletion of asxll results in myeledysplasia[R] .2012ASH Annum Meeting,Abstract,308.
  • 3ALIZADEH A A,EISEN M B,DAVIS R E,et al.Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling[J] .Nature,2000,403:503-511.
  • 4ROSENWALD A,WRIGHT G,CHAN W C,et al.The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma[J] .N Engl J Med,2002,346:1937-1947.
  • 5LENZ G,WRIGHT G,DAVE S S,et al.Stromal gene signatures in large-B-cell lymphomas[J] .N Engl J Med,2008,359:2313-2323.
  • 6MORIN R D,JOHNSON N A,SEVERSON T M,et al.Somatic mutations altering EZH2(Tyr641)in follicular and diffuse large B-cell lymphomas of germinal-center origin[J] .Nat Genet,2010,42:181-185.
  • 7KIRMIZIS A,BARTLEY S M,KUZMICHEV A,et al.Silencing of human polycomb target genes is associated with methylation of histone H3Lys 27[J] .Genes Dev,2004,18:1592-1605.
  • 8QI W,CHAN H,TENG L,et al.Selective inhibition of Ezh2by a small molecule inhibitor blocks tumor cells proliferation[J] .Proc Natl Acad Sci U S A,2012,109:21360-21365.
  • 9MCCABE M T,OTT H M,GANJI G,et al.EZH2inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations[J] .Nature,2012,492:108-112.
  • 10KNUTSON S K,WIGLE T J,WARHOLIC N M,et al.A selective inhibitor of EZH2blocks H3K27methylation and kills mutant lymphoma cells[J] .Nat Chem Biol,2012,8:890-896.

同被引文献18

  • 1Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BcI2 protein co- expression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high- risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program [ J]. Blood, 2013, 121 (20) :4021-4031.
  • 2Perry AM, Crockett D, Dave B J, et al. B - cell lymphoma, un- elassifiable, with features intermediate between diffuse large B - cell lymphoma and burkitt lymphoma: study of 39 eases [ J]. Br J Haematol, 2013, 162( 1 ) :40-49.
  • 3Johnson NA, Slack GW, Savage IQ, et al. Concurrent expression of MYC and Bcl2 in diffuse large B-cell lymphoma treated with rit- uximab plus cyelophosphamide, doxorubiein, vineristine, and prednisone [J]. J Clin Oneol, 2012, 30(28):3452-3459.
  • 4Rantanen S, Monni O, Joensuu H, et al. Causes and conse- quences of Bel2 overexpression in diffuse large B-cell lymphoma ~J]. Leuk Lymphoma, 2001,42(5) :1089-1098.
  • 5Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by im- munohistoehemislry using a tissue microarray [ J]. Blood, 2004, 103(1 ) :275-282.
  • 6Wilson WH, Dunleavy K, Pittaluga S, et al. Phase lI study ofdose-adjusted EPOCH and rituximab in untreated diffuse large B- cell lymphoma with analysis of germinal center and post-germinal center biornarkers [J]. J Clin Oneol, 2008,26(16) :2717-2724.
  • 7Choi WW , Weisenburger DD, Greiner T C, et al. A new immu- nostain algorithm classifies diffuse large B-cell lymphoma into mo- lecular subtypes with high accuracy [ J]. Clin Cancer Res, 2009, 15(17) :5494-5502.
  • 8Gareia-SuOrez J, Flores E, Callejas M,et al. Two weekly dose-ad- justed DA -EPOCH-like chemotherapy with high dose dexameha- sone plus rituximab (DA-EDOCHI4-R)in poor-prognostic untreat- ed diffuse large B-cell lymphoma [J]. Br J Haematal, 2013,160 (4) :510-514.
  • 9Pittaluga S, Shovlin M, Pack S, et al. Concurrent Expression Of MYC/Bel-2 protein in newly diagnosed DLBCL is Not associated with an inferior survival following EPOCH-R therapy[J]. Blood, 2013, 122(21 ) : 3029-9.
  • 10Gatter K, Warnke RA. l)iffuse large B-cell lymphoma. In: Jaffe E S, Stein H, Vardiman J W, eds. World Health Organization clas- sification nf lumors: pathology and genetics of tumors of haemato- poietic and lymphoid tissues [ M]. Lyon: IARC Press, 2001.

引证文献1

二级引证文献23

临床血液学杂志
2014年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部